- This event has passed.
The evolution of chronic pain management research and guidance
March 1 @ 5:00 am - 6:00 pm
The evolution of chronic pain management is a panelist event hosted by of those affected by new guidance and involved in the latest research join to discuss the future of chronic pain management
About this event
Chronic pain, defined as persistent or recurring pain lasting longer than 3 months, is challenging to manage and pharmacological therapies (such as opioids) lack high-quality evidence to support their use in treatment and are associated with increased harm.
In this free webinar, a panel of those affected by new guidance, and involved in the latest research, join to discuss “The evolution of chronic pain management research and guidance”
They will review the clinical implications of 2021 changes, including:
After a four-year review, NICE published guidance titled Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain in April 2021 which highlighted the lack of benefits and associated harms with a number of currently used medications in the treatment of chronic pain. It also encouraged the importance of non-pharmaceutical approaches, harm reduction and patient-centred care.
The BMJ Rapid Recommendation
In September 2021, the BMJ published a Rapid Recommendation ‘Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline’ asking the question ‘What is the role of medical cannabis or cannabinoids for people living with chronic pain because of cancer or non-cancer causes?’ As research into medical cannabis as a therapeutic option in the management of chronic pain continues to grow, this latest recommendation suggests it was appropriate to consider a trial of non-inhaled medical cannabis in patients who had otherwise not responded to first-line therapies.
The UK Medical Cannabis Registry – Chronic Pain outcomes
The year ended with the international peer reviewed journal ‘Expert Review of Clinical Pharmacology’ publishing new data from The UK Medical Cannabis Registry on the first group of UK chronic pain patients treated with medical cannabis. 190 patients were included in the final analysis detailing medium-term quality of life and safety data in patients prescribed medical cannabis by specialists at Sapphire Medical Clinics.
The host, Dr Simon Erridge, Head of Research and Access at Sapphire Medical Clinics and Honorary Clinical Research Fellow at Imperial College London, will be joined by the following panel
- Fibromyalgia Action UK Chair and chronic pain patient – Des Quinn
- First author of The BMJ rapid recommendation on medical cannabis for chronic pain and the senior author of systematic review used to guide to recommendation – Dr Jason Busse
- Chronic Pain Consultant and Medical Advisor at Arthritis Action – Dr Wendy Holden
- Advanced Specialist Pharmacist – Katy McLachlan